CSL Seqirus, a business of CSL (ASX: CSL), has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response ...

The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting ...

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...

GigaGen’s prior work with the DOD produced polyclonal antibodies that can neutralize two botulinum neurotoxins, which are ...

The BARDA funding will support studies to validate the Melbourne, Australia-headquartered firm's flagship FebriDx rapid host-response respiratory infection test in low complexity settings and ...

Ossium Health, a commercial-stage bioengineering company with the first-of-its-kind bone marrow bank for processing and deploying stem cell-based therapies, today announced the signing of a contract ...

The firm will enter studies this month aimed at obtaining CLIA waiver for its FDA-cleared FebriDx assay to distinguish bacterial from non-bacterial infections.

Track the latest bird flu vaccine news, investments, and deals as biotechs respond to rising U.S. cases with innovative ...

A sliver-plated wound dressing made by Bravida Medical and funded by BARDA is already approved for treating mustard ...

The Biomedical Advanced Research and Development Authority (BARDA) is a part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response.